Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Oct;6(4):749–754. doi: 10.1016/j.nurt.2009.08.005

Use of sensory methods for detecting target engagement in clinical trials of new analgesics

Boris A Chizh 1,✉, Christine N Sang 2
PMCID: PMC5084294  PMID: 19789077

Summary

The translation of analgesic efficacy seen in preclinical pain models into the clinic is problematic and is associated with a number of factors that may result in the failure of clinical trials to detect the effect of investigational therapeutic agents. The use of translational pain biomarkers in phase I trials can potentially reduce some of these risks by measuring the interaction between the drug and its target (termed target engagement) in humans. To serve this purpose, sensory tests and other measures of pharmacological activity in nociceptive pathways need to be identified, based on the preclinical profile of the drug being tested and the feasibility of human assessments. Here we discuss some examples to assess the utility of sensory and related pain biomarkers in the early phase of evaluation of novel analgesics for confirmation of target engagement in humans. The emphasis is on the TRPV1 antagonists, but some other target mechanisms are also discussed in examining the validity of this approach.

Key Words: Analgesics, clinical trials, biomarkers, sensory testing, capsaicin, heat, TRPV1, hyperalgesia

References

  • 1.Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–715. doi: 10.1038/nrd1470. [DOI] [PubMed] [Google Scholar]
  • 2.Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs. 2007;8:41–53. [PubMed] [Google Scholar]
  • 3.Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain. 2009;10:556–572. doi: 10.1016/j.jpain.2009.02.002. [DOI] [PubMed] [Google Scholar]
  • 4.Huntjens DR, Spalding DJ, Danhof M, Delia Pasqua OE. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol. 2006;148:396–404. doi: 10.1038/sj.bjp.0706737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816–824. doi: 10.1038/39807. [DOI] [PubMed] [Google Scholar]
  • 6.Szallasi A, Appendino G. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers: are we putting the cart before the horse? J Med Chem. 2004;47:2717–2723. doi: 10.1021/jm030560j. [DOI] [PubMed] [Google Scholar]
  • 7.Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009;78:211–216. doi: 10.1016/j.bcp.2009.02.014. [DOI] [PubMed] [Google Scholar]
  • 8.Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today. 2009;14:56–67. doi: 10.1016/j.drudis.2008.11.005. [DOI] [PubMed] [Google Scholar]
  • 9.Hu HJ, Bhave G, Gereau RW. Prostaglandin and protein kinase A-dependent modulation of vanilloid receptor function by metabotropic glutamate receptor 5: potential mechanism for thermal hyperalgesia. J Neurosci. 2002;22:7444–7452. doi: 10.1523/JNEUROSCI.22-17-07444.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gunthorpe MJ, Benham CD, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci. 2002;23:183–191. doi: 10.1016/S0165-6147(02)01999-5. [DOI] [PubMed] [Google Scholar]
  • 11.Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med. 2006;12:545–554. doi: 10.1016/j.molmed.2006.09.001. [DOI] [PubMed] [Google Scholar]
  • 12.Chizh BA, O’Donnell MB, Napolitano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain. 2007;132:132–141. doi: 10.1016/j.pain.2007.06.006. [DOI] [PubMed] [Google Scholar]
  • 13.Gunthorpe MJ, Hannan SL, Smart D, et al. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther. 2007;321:1183–1192. doi: 10.1124/jpet.106.116657. [DOI] [PubMed] [Google Scholar]
  • 14.Davis JB, Rami HK, Stevens AJ. SB-705498, a clinical candidate with antagonist activity at TRPV1 and efficacy in a wide range of preclinical pain models. Abstr Soc Neurosci 2005:364.2 (abstract; available at http://www.sfn.org).
  • 15.LaMotte RH, Lundberg LE, Torebjörk HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol. 1992;448:749–764. doi: 10.1113/jphysiol.1992.sp019068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.LaMotte RH, Shain CN, Simone DA, Tsai EF. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol. 1991;66:190–211. doi: 10.1152/jn.1991.66.1.190. [DOI] [PubMed] [Google Scholar]
  • 17.Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain. 1989;38:99–107. doi: 10.1016/0304-3959(89)90079-1. [DOI] [PubMed] [Google Scholar]
  • 18.Sang CN, Gracely RH, Max MB, Bennett GJ. Capsaicin-evoked mechanical allodynia and hyperalgesia cross nerve territories: evidence for a central mechanism. Anesthesiology. 1996;85:491–496. doi: 10.1097/00000542-199609000-00007. [DOI] [PubMed] [Google Scholar]
  • 19.Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain. 1998;76:317–325. doi: 10.1016/S0304-3959(98)00062-1. [DOI] [PubMed] [Google Scholar]
  • 20.Benrath J, Gillardon F, Zimmermann M. Differential time courses of skin blood flow and hyperalgesia in the human sunburn reaction following ultraviolet irradiation of the skin. Eur J Pain. 2001;5:155–167. doi: 10.1053/eujp.2001.0229. [DOI] [PubMed] [Google Scholar]
  • 21.Gustorff B, Anzenhofer S, Sycha T, Lehr S, Kress HG. The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg. 2004;98:173–177. doi: 10.1213/01.ANE.0000093224.77281.A5. [DOI] [PubMed] [Google Scholar]
  • 22.Yeomans DC, Proudfit HK. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain. 1996;68:141–150. doi: 10.1016/S0304-3959(96)03177-6. [DOI] [PubMed] [Google Scholar]
  • 23.Geber C, Fondel R, Krämer HH, et al. Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain. J Pain. 2007;8:503–514. doi: 10.1016/j.jpain.2007.01.008. [DOI] [PubMed] [Google Scholar]
  • 24.Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol. 1993;100:35S–41S. doi: 10.1038/jid.1993.21. [DOI] [PubMed] [Google Scholar]
  • 25.Benrath J, Eschenfelder C, Zimmerman M, Gillardon F. Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation. Eur J Pharmacol. 1995;293:87–96. doi: 10.1016/0926-6917(95)90022-5. [DOI] [PubMed] [Google Scholar]
  • 26.Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000;288:306–313. doi: 10.1126/science.288.5464.306. [DOI] [PubMed] [Google Scholar]
  • 27.Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 2000;405:183–187. doi: 10.1038/35012076. [DOI] [PubMed] [Google Scholar]
  • 28.García-Martinez C, Humet M, Planells-Cases R, et al. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Natl Acad Sci U S A. 2002;99:2374–2379. doi: 10.1073/pnas.022285899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci. 2001;24:487–517. doi: 10.1146/annurev.neuro.24.1.487. [DOI] [PubMed] [Google Scholar]
  • 30.Krause JE, Chenard BL, Cortright DN. Transient receptor potential ion channels as targets for the discovery of pain therapeutics. Curr Opin Investig Drugs. 2005;6:48–57. [PubMed] [Google Scholar]
  • 31.Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des. 2008;14:32–41. doi: 10.2174/138161208783330754. [DOI] [PubMed] [Google Scholar]
  • 32.Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin: a microdialysis study. J Invest Dermatol. 2000;115:1015–1020. doi: 10.1046/j.1523-1747.2000.00142.x. [DOI] [PubMed] [Google Scholar]
  • 33.Sauerstein K, Klede M, Hilliges M, Schmelz M. Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin. J Physiol. 2000;529:803–810. doi: 10.1111/j.1469-7793.2000.00803.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schmelz M, Michael K, Weidner C, Schmidt R, Torebjörk HE, Handwerker HO. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport. 2000;11:645–648. doi: 10.1097/00001756-200002280-00041. [DOI] [PubMed] [Google Scholar]
  • 35.Klede M, Clough G, Lischetzki G, Schmelz M. The effect of the nitric oxide synthase inhibitor N-nitro-l-arginine-methyl ester on neuropeptide-induced vasodilation and protein extravasation in human skin. J Vasc Res. 2003;40:105–114. doi: 10.1159/000070707. [DOI] [PubMed] [Google Scholar]
  • 36.Koppert W, Dern SK, Sittl R, Albrecht S, Schüttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology. 2001;95:395–402. doi: 10.1097/00000542-200108000-00022. [DOI] [PubMed] [Google Scholar]
  • 37.Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain. 2000;85:217–224. doi: 10.1016/S0304-3959(99)00268-7. [DOI] [PubMed] [Google Scholar]
  • 38.Klede M, Handwerker HO, Schmelz M. Central origin of secondary mechanical hyperalgesia. J Neurophysiol. 2003;90:353–359. doi: 10.1152/jn.01136.2002. [DOI] [PubMed] [Google Scholar]
  • 39.Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005;(4):CD003345. [DOI] [PMC free article] [PubMed]
  • 40.Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008;324:416–421. doi: 10.1124/jpet.107.130344. [DOI] [PubMed] [Google Scholar]
  • 41.de Hoon J, de Lepeleire I, Hickey L, et al. Inhibition of capsaicin-induced increase in dermal microvascular blood flow by the oral CGRP antagonist, MK-0974. Cephalalgia. 2007;27:738–739. [Google Scholar]
  • 42.Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28:580–587. doi: 10.1016/j.tips.2007.10.005. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES